|
1
|
Lozano R, Naghavi M, Foreman K, et al:
Global and regional mortality from 235 causes of death for 20 age
groups in 1990 and 2010: A systematic analysis for the Global
Burden of Disease Study 2010. Lancet. 380:2095–2128. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vacca M, Degirolamo C, Mariani-Costantini
R, Palasciano G and Moschetta A: Lipid-sensing nuclear receptors in
the pathophysiology and treatment of the metabolic syndrome. Wiley
Interdiscip Rev Syst Biol Med. 3:562–587. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Calkin AC and Tontonoz P: Transcriptional
integration of metabolism by the nuclear sterol-activated receptors
LXR and FXR. Nat Rev Mol Cell Biol. 13:213–224. 2012.PubMed/NCBI
|
|
4
|
Chawla A, Boisvert WA, Lee CH, et al: A
PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in
cholesterol efflux and atherogenesis. Mol Cell. 7:161–171. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Venkateswaran A, Laffitte BA, Joseph SB,
et al: Control of cellular cholesterol efflux by the nuclear
oxysterol receptor LXR alpha. Proc Natl Acad Sci USA.
97:12097–12102. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Naik SU, Wang X, Da Silva JS, et al:
Pharmacological activation of liver X receptors promotes reverse
cholesterol transport in vivo. Circulation. 113:90–97. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun AL, Feng L and Liu RM: Preparative
isolation and purification of honokiol and magnolol from Magnolia
officinalis Rehd. et Wils by high-speed countercurrent
chromatography. Fen Xi Hua Xue Bian Ji Bu. 33:1016–1018. 2005.[(In
Chinese)].
|
|
8
|
Wang ZQ, Mi W, Liu XB, et al: The in vitro
growth-inhibitory effect of Magnolia officinalis Rehd. et Wils.
(MOR) on bacteria. Shizhen Guo Yi Guo Yao. 18:27632007.[(In
Chinese)].
|
|
9
|
Zhang WW, Li Y, Wang XQ, et al: Effects of
magnolol and honokiol derived from traditional Chinese herbal
remedies on gastrointestinal movement. World J Gastroenterol.
11:4414–4418. 2005.PubMed/NCBI
|
|
10
|
Ren SC, Fan YC and Li CC: Inhibitory
effects of 30 kinds of Chinese herbal medicine on fungi in food.
Adv Mater Res. 343-344:737–742. 2012.
|
|
11
|
Yang QH, Yang HW, Xie F and Zhang YP:
Experimental study of Jiangzhi Ninggan capsules on rat model with
fatty liver disease. Liaoning Zhong Yi Zazhi Bianji Bu.
35:1420–1422. 2008.[(In Chinese)].
|
|
12
|
Kotani H, Tanabe H, Mizukami H, Amagaya S
and Inoue M: A naturally occurring rexinoid, honokiol, can serve as
a regulator of various retinoid x receptor heterodimers. Biol Pharm
Bull. 35:1–9. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Houck KA, Borchert KM, Hepler CD, Thomas
JS, Bramlett KS, Michael LF and Burris TP: T0901317 is a dual
LXR/FXR agonist. Mol Genet Metab. 83:184–187. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen CR, Tan R, Qu WM, et al: Magnolol, a
major bioactive constituent of the bark of Magnolia officinalis,
exerts antiepileptic effects via the GABA/benzodiazepine receptor
complex in mice. Br J Pharmacol. 164:1534–1546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kumar S, Guru SK, Pathania AS, Kumar A,
Bhushan S and Malik F: Autophagy triggered by magnolol derivative
negatively regulates angiogenesis. Cell Death Dis. 4:e8892013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y and Tang F: Advance in latest
studies on pharmacological effects of magnolol. Zhongguo Zhong Yao
Za Zhi. 37:3526–3530. 2012.[(In Chinese)]. PubMed/NCBI
|
|
17
|
Lee YJ, Lee YM, Lee CK, Jung JK, Han SB
and Hong JT: Therapeutic applications of compounds in the Magnolia
family. Pharmacol Ther. 130:157–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vaughan AM and Oram JF: ABCA1 and ABCG1 or
ABCG4 act sequentially to remove cellular cholesterol and generate
cholesterol-rich HDL. J Lipid Res. 47:2433–2443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grefhorst A, Oosterveer MH, Brufau G,
Boesjes M, Kuipers F and Groen AK: Pharmacological LXR activation
reduces presence of SR-B1 in liver membranes contributing to
LXR-mediated induction of HDL-cholesterol. Atherosclerosis.
222:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X and Paigen B: Genetics of variation
in HDL cholesterol in humans and mice. Circ Res. 96:27–42. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yasuda T, Grillot D, Billheimer JT, Briand
F, Delerive P, Huet S and Rader DJ: Tissue-specific liver X
receptor activation promotes macrophage reverse cholesterol
transport in vivo. Arterioscler Thromb Vasc Biol. 30:781–786. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Linsel-Nitschke P and Tall AR: HDL as a
target in the treatment of atherosclerotic cardiovascular disease.
Nat Rev Drug Discov. 4:193–205. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Degoma EM and Rader DJ: Novel HDL-directed
pharmacotherapeutic strategies. Nat Rev Cardiol. 8:266–277. 2011.
View Article : Google Scholar : PubMed/NCBI
|
